Joseph Y. Rho

Joseph Y. Rho

Auto-generated profile, based on publicly available information

Joseph Y. Rho

Department of Ortho- pedic Surgery Jeju National University Hospital Jeju Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of the Korean Fracture Society
Verified
Journal Article
Open access
PDF file
YRYoung-Ho Roh
Young-Ho Roh
JRJoseph Rho
Joseph Rho
KNKwang Woo Nam
Kwang Woo Nam
Roh YH, et al. J Korean Fract Soc. 2019 Jan;32(1):35-42. https://doi.org/10.12671/jkfs.2019.32.1.35

30 June 2023 in Journal of Medicine and Life Science
Verified
Journal Article
Open access
PDF file
SCSung-Wook Choi
Sung-Wook Choi
SYSeong-Meen Yoon
Seong-Meen Yoon
JRJoseph Y. Rho
Joseph Y. Rho
ISIn-seok Son
In-seok Son
Gentamicin-loaded bone cement used in total joint arthroplasty is indispensable, as it provides stability by directly binding the surfaces of implants and bones. Depending on multiple factors, including the material of the bone cement used, common complications, such as aseptic loosening, osteolysis, and infection can occur postoperatively. In clinical practice, Doujet bone cement is easy to handle (pre-packed all-in-one system), and has shown low failure rates and non-inferior results compared with similar available products. We conducted a retrospective comparative study to analyze the clinical and radiological results of each bone cement group to establish the safety and usefulness of Doujet bone cement. From July 2020 to July 2022, we enrolled 198 patients in this study after an average follow-up period of 37 months (range, 6–48 months). In 99 patents, Doujet® bone cement (Injecta, Gunpo, Korea) was used for total knee arthroplasty (TKA), while Refobacin® bone cement (Biomet, Warsaw, IN, USA) was used in 99 patients. The average range of motion (ROM) of the knee increased by 2.4° (from 127.0° preoperatively to 129.4° postoperatively) in the Doujet group, and by 0.1° (from 128.7° to 128.8°) in the Refobacin group (P=0.701). The Western Ontario and McMaster Universities (WOMAC) osteoarthritis index scores decreased from 44.1 to 7.8 in the Doujet group, and from 44.2 to 6.3 in the Refobacin group (P=0.162). Complications, such as osteolysis or post-operative wound infection, did not occur in more than two cases in both groups. The WOMAC and ROM of the knee in both groups had no clinical differences. Both Doujet and Refobacin similarly showed low complication rates after TKA.